About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 5671 record(s)
Req # A-2024-000007
Adverse Drug Reactions (ADRs) for Heparin. Report numbers: 001072985.Organization: Health Canada
April 2024
Req # A-2024-000012
Adverse Drug Reactions (ADRs). Report numbers: 001067949, 001069982.Organization: Health Canada
April 2024
Req # A-2024-000017
Adverse Drug Reaction (ADR) for ACITRETIN. Report number: 1071472. ADRs for ANASTROZOLE. Report numbers: 983160, 990116. ADR for CIPROFLOX. Report number: 1032025. ADR for Clonidine. Report number: 981372. ADRs for EPLERENONE. Reports number: 1026516, 1043922. ADRs for HYDROXYCHLOROQUINE. Report numbers: 1024918, 1026702, 1037377.Organization: Health Canada
April 2024
Req # A-2024-000028
Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report numbers: 000709470, 000720165.Organization: Health Canada
April 2024
Req # A-2024-000032
Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.Organization: Health Canada
April 2024
Req # A-2024-000068
Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.Organization: Health Canada
April 2024
Req # A-2023-00038
A copy of the Staffing Information Manual. Limit to the most recent final version in English.Organization: Public Service Commission of Canada
April 2024
Req # A-2024-00001
The number of advertised EX-1 job competitions conducted/advertised on jobs.gc.ca between January 1, 2023, and April 1, 2024, that were: 1) advertised processes for indeterminate EX-1 positions or equivalent (excluding casual, inventory, or at-level assignments) 2) open to all members of the public service occupying positions in the National Capital Region (excluding other regions and competitions open exclusively to one department) 3) not restricted (in essential criteria or assessment qualifications) to members of an employment equity group, or veterans (excluding all positions for which being a member of an employment equity group or being a veteran was a pre-requirement)Organization: Public Service Commission of Canada
April 2024
Nothing to report this month
Organization: Office of the Intelligence Commissioner
Req # A-2016-000420
Documents relating to Health Canada’s approval of INFLECTRA (Drug Identification Number (DIN) # 02419475): All Health Canada reviewers reports and reviewer comments; and all minutes from any pre-Supplement to a New Drug Submission (SNDS) meetings between Celltrion (health care company) and Health Canada between September 1, 2014 and June 30, 2015.Organization: Health Canada
March 2024